Ashley L Devonshire, Theresa Guilbert, Cindy S Bauer, Heidi Schmidt, Stephanie Davis, Michelle Hernandez, Anne M Fitzpatrick, Jonathan M Gaffin, Meyer Kattan, Aliva De, Daniel J Jackson, David Mauger, Wanda Phipatanakul, Justin T Schwartz, William Sheehan, Dayna Long, Lourdes Juarez, Leonard B Bacharier, Jeffrey R Stokes, Stephen J Teach, Wayne J Morgan, Fernando D Martinez
{"title":"Evaluating the Impact of the COVID-19 Pandemic on Pediatric Asthma Incidence.","authors":"Ashley L Devonshire, Theresa Guilbert, Cindy S Bauer, Heidi Schmidt, Stephanie Davis, Michelle Hernandez, Anne M Fitzpatrick, Jonathan M Gaffin, Meyer Kattan, Aliva De, Daniel J Jackson, David Mauger, Wanda Phipatanakul, Justin T Schwartz, William Sheehan, Dayna Long, Lourdes Juarez, Leonard B Bacharier, Jeffrey R Stokes, Stephen J Teach, Wayne J Morgan, Fernando D Martinez","doi":"10.1016/j.jaip.2025.04.056","DOIUrl":null,"url":null,"abstract":"<p><p>Multiple early life environmental exposures are thought to influence childhood asthma incidence. The COVID-19 pandemic resulted in changes to air pollution levels and a marked disruption in the circulation of childhood respiratory viruses. Both air pollution and respiratory viruses have been implicated in the development of asthma and early childhood wheeze. Human behavior and daily routine practices, including family gatherings and daycare attendance, were impacted profoundly by the COVID-19 pandemic and the associated mitigation efforts put into place during this time. The changes to human behavior and social interactions that occurred during the pandemic have and will likely continue to impact chronic diseases, including the development of asthma. This rostrum explores how childhood asthma incidence might be affected by the COVID-19 pandemic and its associated public health mitigation measures. Recently completed and ongoing clinical trials being conducted in the infant and toddler population and assessing allergic outcomes may be well positioned to examine the impact of the pandemic on asthma incidence and time to asthma onset.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology-In Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jaip.2025.04.056","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
Abstract
Multiple early life environmental exposures are thought to influence childhood asthma incidence. The COVID-19 pandemic resulted in changes to air pollution levels and a marked disruption in the circulation of childhood respiratory viruses. Both air pollution and respiratory viruses have been implicated in the development of asthma and early childhood wheeze. Human behavior and daily routine practices, including family gatherings and daycare attendance, were impacted profoundly by the COVID-19 pandemic and the associated mitigation efforts put into place during this time. The changes to human behavior and social interactions that occurred during the pandemic have and will likely continue to impact chronic diseases, including the development of asthma. This rostrum explores how childhood asthma incidence might be affected by the COVID-19 pandemic and its associated public health mitigation measures. Recently completed and ongoing clinical trials being conducted in the infant and toddler population and assessing allergic outcomes may be well positioned to examine the impact of the pandemic on asthma incidence and time to asthma onset.
期刊介绍:
JACI: In Practice is an official publication of the American Academy of Allergy, Asthma & Immunology (AAAAI). It is a companion title to The Journal of Allergy and Clinical Immunology, and it aims to provide timely clinical papers, case reports, and management recommendations to clinical allergists and other physicians dealing with allergic and immunologic diseases in their practice. The mission of JACI: In Practice is to offer valid and impactful information that supports evidence-based clinical decisions in the diagnosis and management of asthma, allergies, immunologic conditions, and related diseases.
This journal publishes articles on various conditions treated by allergist-immunologists, including food allergy, respiratory disorders (such as asthma, rhinitis, nasal polyps, sinusitis, cough, ABPA, and hypersensitivity pneumonitis), drug allergy, insect sting allergy, anaphylaxis, dermatologic disorders (such as atopic dermatitis, contact dermatitis, urticaria, angioedema, and HAE), immunodeficiency, autoinflammatory syndromes, eosinophilic disorders, and mast cell disorders.
The focus of the journal is on providing cutting-edge clinical information that practitioners can use in their everyday practice or to acquire new knowledge and skills for the benefit of their patients. However, mechanistic or translational studies without immediate or near future clinical relevance, as well as animal studies, are not within the scope of the journal.